Objective. To study the effects of low-dose prednisolone on the osteoclast-regulating proteins osteoprotegerin (OPG) and RANK ligand (RANKL) and on markers of bone resorption, 1CTP generated by MMPs and CTX-1 generated by cathepsin K, in patients with early RA in relation to inflammation and joint destruction.
Introduction
Low-dose prednisolone, mostly given together with DMARDs, reduces symptoms of inflammation as well as progression of radiographically visible joint damage in hands and feet in early RA [13] . In some trials, however, the prednisolone-specific reduction of inflammation was evident only during the first 6 months of therapy, whereas the hampering of joint destruction was maintained over 2 years [1, 3] . Further, patients in remission after 2 years had less joint destruction if they had been treated with prednisolone in combination with DMARDs than patients in remission on only DMARDs [4] .
It is thus suggested that low-dose prednisolone may affect joint destruction not only by reducing inflammation but also by other mechanisms. Like treatment with anti-TNF-a, prednisolone may uncouple the relationship between inflammation and radiographic progression [5, 6] .
A possible mechanism by which prednisolone may retard bone damage is affection of the cell-surface molecule RANK ligand (RANKL) or the soluble receptor-like molecule osteoprotegerin (OPG) [7] . RANKL, bound to its receptor RANK, stimulates formation and activation of osteoclasts [8] , which have a critical role in the pathogenesis of bone erosions in RA [9] . Further, treatment with antibodies against RANKL, denosumab, has been shown to inhibit structural damage of the joints [10] . OPG, the decoy receptor for RANKL that binds RANKL and inhibits its biologic activity, almost completely blocks the development of joint erosions in a rat model of adjuvant arthritis [11] .
Another way to better understand the role of prednisolone in inhibiting joint destruction is to study its effects on bone resorption products such as C-terminal telopeptide crosslaps (CTX-1) and C-terminal telopeptides of type I collagen (1CTP). These fragments reflect different resorption processes: CTX is generated by cathepsin K, whereas 1CTP is generated by MMPs, whose activities are essential in collagen degradation in arthritis [12] . In RA, the SF/ serum ratio is increased for 1CTP, but not for CTX-1, indicating a preferential local joint production of 1CTP [13] . As low-dose prednisolone reduces CTX-1 and 1CTP differently [14] , we hypothesize that reduction of 1CTP is one mechanism by which prednisolone reduces joint damage.
The purpose of the present study was to study the effects of low-dose prednisolone on the osteoclastregulating proteins OPG and RANKL and on the two markers of bone resorption, 1CTP and CTX-1, in patients with early RA in relation to inflammation and joint destruction.
Patients and methods

Patients
Two hundred and twenty-five of the 250 patients with early RA, who had participated in the BARFOT (Better Anti-Rheumatic FarmacOTherapy) low-dose prednisolone study [2] were included in this mechanistic study. Briefly, these patients, 64% women, had a diagnosis of RA according to the ACR criteria [15] , were between 18 and 80 years of age [mean (S.D.) 54.8 (13.9) years], had a disease duration of <1 year [mean (S.D.) 6.2 (3.2) months] and had active disease defined as a DAS28 of >3.0 [mean (S.D.) 5.4 (1.1)]. The patients were randomized to treatment with 7.5 mg prednisolone daily (P-group, 108 patients) for 2 years or no prednisolone (NoP-group, 117 patients) when they started with the first DMARD. Concerning the DMARDs 83% of the patients started with either MTX or SSZ. In the P-group, 48% started with MTX and 35% with SSZ. The corresponding figures for the NoP-group were 54% and 37%. The patients were followed up prospectively for 2 years.
To be included in this mechanistic study, the patients should have X-rays of hands and feet performed both at baseline and at the 2-year follow-up visit. These 225 patients did not differ in baseline clinical characteristics from the 25 patients in the main study lacking radiographs.
All patients gave informed written consent to enter the study, which was approved by the ethics committees at Karolinska University Hospital, Lund University Hospital, Sahlgrenska University Hospital in Gothenburg and Linkö ping University Hospital and was performed according to the Declaration of Helsinki.
Clinical assessments
Disease activity was assessed by DAS28 [16] . Remission was defined as DAS28 <2.6. Functional status was measured using the Swedish version of the Stanford HAQ [17] . The HAQ score ranges from 0 to 3, where a higher score indicates a higher degree of disability.
Laboratory assessments
Serum samples were obtained between 9 a.m. and 3 p.m. and stored at À70 C until assay. All samples from the individual patient were analysed simultaneously to minimize inter-assay variations.
RANKL and OPG were analysed at Molecular Periodontology, Umeå University at 0, 3, 12 and 24 months with commercially available ELISA kits. The concentration of RANKL was assessed using a kit detecting free human soluble RANKL (ampli-sRANKL, Biomedica Medizinprodukte GmbH, Vienna, Austria). The detection limit is 0.02 pmol/l according to the supplier, but as some patients had values below that we also used these values, when measurable, to avoid false zero values. The intra-assay variation was found to be 6.9% [n = 20; mean value (mv) 0.37 pmol/l]. OPG was analysed using a kit detecting free OPG as well as complexed OPG/RANKL (Biomedica Medizinprodukte GmbH) with a detection limit at 0.14 pmol/l and an intra-assay variation of 5.4% (n = 20; mv 2.5 pmol/l).
CTX-1 and 1CTP were analysed at 0, 3 and 12 months at the Study Centre for Laboratory Medicine, Karolinska University Laboratory, Stockholm, Sweden. CTX-1 was determined by Elecsys 1010/2010 b-CrossLaps serum kit from Roche Diagnostics, Mannheim, Germany, which employs the electrochemiluminescence immunoassay technique [14] . 1CTP was determined by Multigamma radioimmunoassay kit from Orion Diagnostica, Espoo, Finland [14] .
Radiographic evaluation
Anteriorposterior radiographs of hands and forefeet were performed at study entry and after 1 and 2 years. The radiological damage was scored according to the van der Heijde modification of the Sharp score (SHS) [18] with separate presentation of total Sharp score (TSS; range 0448), erosion score (ES; range 0280) and joint space narrowing score (JSN; range 0168). Two specially trained readers assessed the radiographs in chronological order [2] . Radiological progression was defined as an increase in TSS above 5.8, the smallest detectable change.
Statistics
STATISTICA release 8 from Stat Soft Scandinavia AB (Tulsa, OK, USA), SAS System 9.1 (SAS Institute Inc., Cary, NC, USA) and SPSS 18.0 (IBM Corporation, Armonk, NY, USA) were used for statistical analyses. Data are presented as mean (S.D.) or median [interquartile range (IQR)] depending on their distribution. Correlation analyses were performed with Spearman rank order correlations. P < 0.05 was considered statistically significant.
CTX-1, 1CTP and OPG were analysed using a mixed linear model [19] with two between-subject factors, Treat (A and B) and Remission after 24 months (yes/no), and one within-subject factor Time (0, 3, 12 and 24 months) and all possible interactions between the factors. The random effect in the model is the subjects. In a mixed model there are no problems caused by missing data, provided that missing data can be assumed to be missing at random. Different covariance models were tested and the covariance structure with the smallest value of the Akaike and Bayesian Information Criteria was considered to best fit the data (unstructured for CTX, 1CTP and OPG, and compound symmetry for RANKL and the ratio OPG/RANKL). Fitting covariance pattern models leads to more appropriate fixed-effects estimates and standard errors. In case of significant interactions, simple main effect tests were performed, i.e. effects of one factor holding the level of the other factors fixed. The distribution of the variables was positively skewed and before the formal analyses the variables 1CTP, TSS, ES and JSN were log-transformed and CTX and OPG square root transformed.
As a high frequency of the sRANKL values was reported as zero or below zero we adjusted those values to 0.001. Due to the floor effect of the truncated scale of sRANKL the variable was divided into four categories: 0.001; >0.001 to 0.032; >0.032 to 0.1280; and >0.1280 on the basis of quartiles. This ordinal response ranging from 1 to 4 was subsequently analysed by fitting a generalized estimating equations (GEE) model with the GENMOD procedure in SAS [20] . The first quartile was used as reference for other categories. The same procedure was performed for the ratio between OPG and RANKL, which was divided into the following four categories: 424.9; >24.9 to 122.3, >122.3 to 3796; and >3796. The GEE strategy is a useful approach for repeated-measurements analysis of ordered categorical outcomes. With an ordinal response model the only correlation structure available is the independent. The GEE method handles missing values but requires the missing data to be missing at random. The model was set up with the same factors as in the mixed linear model mentioned above. The parameter estimates from the GEE model were presented as odds ratios and 95% CI.
A generalized linear model was carried out with change in TSS as dependent variable, change in a biomarker as covariate (1CTP, CTX-1 baseline to 12 months, OPG or RANKL baseline to 24 months) and treatment group (prednisolone or no prednisolone) as factor. Into additional models remission status at 24 months was added to determine the impact of remission.
Results
Baseline demographics and clinical characteristics of the patients are presented in Table 1 .
Prednisolone and concomitant treatment
Of the 108 patients randomized to prednisolone treatment, 8 stopped treatment because of side effects or unwillingness to continue prednisolone treatment. Of the 117 patients randomized to no prednisolone treatment, 6 patients started prednisolone treatment due to increased disease activity. The patients have been analysed in the group that they were randomized to. After 24 months, 16% in the P-group and 17% in the NoP-group were no longer taking DMARDs and several patients in each group had switched from treatment with SSZ to MTX.
Disease activity and remission
Mean DAS28 had decreased significantly at 12 months as well as at 24 months in both treatment groups and was significantly lower in the P-group at both time points. At 24 months DAS28 was 2.7 (1.3) in the P-group and 3.2 (1.4) in the NoP-group, P = 0.010. After 12 months remission was achieved in 49% of the patients in the P-group compared with 38% of the patients in the NoP-group, P = 0.10 and www.rheumatology.oxfordjournals.org after 24 months the remission rate was 57% vs 33%, P < 0.001, respectively. For all patients, 72% of those in remission at 24 months were already in remission at 12 months. The figures for patients in the P-and NoP-group were 71% and 74%, respectively.
OPG and RANKL
Between baseline (0) and 3 months, OPG increased in both the P-group and the NoP-group, P = 0.015 and P < 0.001, respectively, with no significant difference between groups (Table 2) . However, between 0 and 24 months the change in OPG was significantly different between the treatment groups, P = 0.032 (Table 2) , with a decrease in the P-group, P = 0.015, and a stable value in the NoP-group, P = 0.53.
Concerning RANKL there was no significant change in the P-group, 012 months P = 0.69 and 024 months P = 0.46, whereas there was a significant increase in RANKL at 12 and 24 months in the NoP-group, P = 0.030 and P = 0.020, respectively. The difference between the treatment groups in RANKL change 024 months was significant (P = 0.025, Table 3 ).
The ratio OPG/RANKL was stable in the P-group after 12 and 24 months, P = 0.36 and 0.67, respectively, whereas in the NoP-group the ratio had decreased significantly at 12 and 24 months, P = 0.021 and 0.025, respectively. The difference between the treatment groups was significant at 12 months, P = 0.020, and there was a trend for a difference also at 24 months (P = 0.059, Table 3 ).
In a separate analysis of patients in remission, the change in OPG 024 months was significantly different between the treatment groups, with decreasing levels only in the P-group (P = 0.028, Table 4 ). For patients not in remission the decrease in OPG did not differ between the treatment groups. As to the changes in RANKL and the ratio OPG/RANKL, there were no significant differences between treatment groups in patients in remission or not (Table 5) . Data are presented as odds ratio (OR) with 95% CI within parentheses. RANKL and OPG/RANKL were categorized in four different classes and analysed using the GENMOD procedure. P-values are given for the differences between the treatment groups (Treat), time points as well as for the interaction between Time and Treatment, i.e. the differences between the groups with respect to the differences between the baseline values and the values at 3, 12 and 24 months. 
<0.001
Data are presented as median (IQR). Data were analysed using a mixed linear model with the variables log-(1CTP) or square-(CTX and OPG) transformed. The P-values correspond to the interaction between treatment time remission, where we analysed the differences between the groups, within each remission group, with respect to the differences between the baseline values and the values at 3, 12 and 24 months. Data are presented as odds ratio with 95% CI within parentheses. RANKL and OPG/RANKL were categorized in four different classes and analysed using the GENMOD procedure. For P-values, see explanation in Table 4 . a Variables that are included in the interaction calculations.
www.rheumatology.oxfordjournals.org 1CTP and CTX-1 1CTP had increased after the first 3 months in patients not treated with prednisolone, P = 0.006, whereas it had decreased in patients treated with prednisolone after 3 and 12 months, P < 0.001 and P < 0.001, respectively. There was a significant difference between the treatment groups over time (Table 2) . CTX-1 decreased significantly in both treatment groups, but significantly more in the P-group at both 3 and 12 months, P = 0.011 and 0.005, respectively (Table 2) , and there was also a significant difference between the treatment groups over time.
When studying the patients in remission and not in remission separately, it was found that the decrease in 1CTP in the P-group over time was more pronounced compared with that in the NoP-group, irrespective of whether the patients were in remission or not (Table 4 ). The CTX-1 reduction did not differ between treatment groups for patients in remission, whereas it was significantly more pronounced in the P-group compared with the NoP-group in patients not in remission (Table 4) .
Radiological scores
Radiological scores at baseline are presented in Table 1 . As previously reported [2], the patients in the P-group had significantly less increase in TSS and ES but not in JSN at 12 and 24 months compared with the patients in the NoP-group.
In patients in remission at 24 months, prednisolonetreated patients showed less increase in TSS at 12 and 24 months (P = 0.009 and 0.023) and in ES at 12 months (P = 0.011), in comparison with patients without prednisolone (Table 6 ). In patients not in remission, there were no significant differences in radiological scores between patients treated with prednisolone or not ( Table 6 ). The proportion of patients with radiological progression (progressors) at 24 months was in the P-group 26% vs 39% in the NoP-group (P = 0.033).
Associations between TSS and bone markers
Patients with radiographic progression after 2 years had significantly higher levels of 1CTP at baseline and after 12 months compared with patients with no radiographic progression, P = 0.029 and P < 0.001, respectively. There were no significant differences in levels of OPG, RANKL and CTX-1 or the ratio OPG/RANKL at these time-points between progressors and non-progressors. A correlation analysis showed a significant positive correlation between 1CTP and TSS both at baseline, R = 0.26, P < 0.001 and at 12 months, R = 0.36, P < 0.001.
A generalized linear model showed that treatment group and change in 1CTP were significant predictors (P = 0.041 and 0.03) of change in TSS. In addition, there was a significant interaction between them (P = 0.020). Thus, the relationship between change in 1CTP and change in TSS differed between treatment groups. However, there was no significant interaction between treatment group and change in CTX-1, change in OPG or change in RANKL, P = 0.19, P = 0.52 and P = 0.77, respectively.
Remission state (yes/no) at 2 years was then added as a factor to the model and was found to be significantly associated with change in TSS, P = 0.004. The interaction between treatment group and change in 1CTP still remained significant, although to a lesser extent (P = 0.046). This implies that the relationship between change in 1CTP and change in TSS differed between treatment groups also when remission status was included in the model. The same pattern was seen in a further model, in which change in DAS28 between baseline and 2 years was substituted for remission state (data not shown).
Discussion
In the present study, in which patients with early RA had been randomized to prednisolone or no prednisolone, we analysed possible mechanisms by which prednisolone reduced joint destruction. We found that in patients treated with prednisolone the OPG/RANKL ratio was stable, in contrast to those not receiving prednisolone in whom the ratio decreased. Further, CTX-1 decreased significantly more in the P-group than in the NoP-group. These effects are interpreted as due to more pronounced reduction of disease activity by prednisolone treatment. 1CTP, too, decreased significantly more in the P-group and this decrease was associated with less joint destruction. The reduction of 1CTP by prednisolone treatment points to a specific effect of prednisolone since it was only partly dependent on reduced inflammation.
Biochemical markers of the inflammatory process and of bone degradation have been extensively studied to find predictors at RA onset to subsequent joint destruction [2130] . However, studies concerning the impact of how different treatment strategies affect these markers and how changes of these correlate to radiological outcome are limited.
The hampering effect of prednisolone only on the progression of erosions and not on JSN supports that the mechanisms behind destruction of bone and cartilage are different, although both are partly dependent on inflammation. Thus, osteoclasts are pivotal cells for bone resorption in destructive arthritis and RANKL essential for bone erosions but not for cartilage destruction [31, 32] . RANKL has been detected in the synovium of collagen-induced rat arthritis [33] but not in normal synovium. Expression of RANKL mRNA has also been found in synovium from patients with RA [9] .
In the present study, OPG and RANKL were lower than earlier reported in patients with active RA [34] . This discrepancy can partly be attributed to different patient characteristics and varying laboratory methods. Here, sRANKL was measured, which represents free RANKL able to bind and activate RANK. However, the large portion of RANKL in serum is bound to OPG and maybe also to other proteins. To what extent sRANKL represents truncated cleared extracellular portion of cell-bound RANKL or secreted RANKL is not known, nor is it known which cells produce sRANKL in serum [35] . Almost one-third of the patients had undetectable levels of RANKL at baseline. Despite that, the change in RANKL was significantly different between the treatment groups with an increase in RANKL in the NoP-group and stable levels in the P-group. The reason that we could not detect any decrease in RANKL may be due to the low detection levels at baseline.
The reduction in OPG was more pronounced in patients treated with prednisolone, which is in accordance with previous studies showing that hydrocortisone and dexamethasone decrease OPG mRNA in cultured osteoblasts [36] . Further, as patients in remission had higher reduction of OPG if treated with prednisolone than those not treated with prednisolone, a specific effect of prednisolone should be considered. Despite the decrease in OPG in the P-group this group showed a stable ratio between OPG and RANKL in contrast to a decreased ratio in the NoP-group. This finding supports the presence of decreased osteoclast activation in the prednisolonetreated patients, as the balance between OPG and RANKL regulates osteoclast activity.
The importance of OPG, RANKL and of the ratio OPG/ RANKL for joint destruction has been emphasized in the last years. For example, treatment with antibodies against RANKL, denosumab, inhibits structural damage of the joints [10] . Furthermore, in the Combinatietherapie Bij Reumatoïde Artritis (COBRA) study, radiographic progression after 5 years was negatively associated with the ratio OPG/RANKL at baseline [24] . The reason for the lack of correlation between the ratio OPG/RANKL and radiological progression in the present study may depend on the fact that we only analysed sRANKL.
Interestingly, the interaction between treatment and change in 1CTP was a significant predictor of change in TSS. This implies that the reduction of 1CTP was mediated not only by reduced disease activity but also by some prednisolone-specific mechanism. 1CTP is released from the peri-articular bone by the action of MMP, which is an essential collagen-degrading proteinase in RA pannus and involved in synovial invasion [37] . 1CTP has thus been considered a sensitive marker for detecting increased local joint tissue turnover and has been shown to correlate with joint inflammation [38] .
The more pronounced reduction of 1CTP seen in prednisolone-treated patients together with less radiological progression in these patients suggests down-regulation of the synthesis of matrix-degrading enzymes, such as MMP-1 in the synovial membrane, and may therefore be one mechanism by which prednisolone protects inflamed joints from structural damage [39] . In addition, 1CTP decreased during treatment with infliximab, correlating with the clinical efficacy of the treatment [40] . However, to our knowledge, the impact of TNF-blockade on 1CTP levels in relation to joint destruction has not been studied. Therefore, it is not known if the disconnect between inflammation and joint destruction, demonstrated by TNF blockade [5, 6] , may partly be mediated by reduction of collagen-degrading proteinases causing release of 1CTP.
The decrease of CTX-1 in both treatment groups, more pronounced in the P-group, seemed to be related to the reduced inflammation. This idea is supported by the finding that, in patients achieving remission, the CTX-1 decrease was similar irrespective of prednisolone treatment or not. In addition, in earlier cross-sectional and longitudinal studies CTX-1 levels correlated positively with disease activity [5, 41] and reflected bone turnover [42] .
Reports concerning the ability of CTX-1 to predict joint destruction are conflicting. Thus, in patients with early RA, 60% of whom were treated with glucocorticoids, baseline CTX-1 predicted progression of joint destruction [28] . Further, in the COBRA study, irrespective of therapy given, high baseline levels of urinary CTX-1 independently predicted increased risk of radiological progression over 4 years [23] . However, in the same patients, longitudinal analysis showed a significant decrease of CTX-1, but the decrease at 3, 6 and 12 months was not associated with progression of joint destruction at 5 years [43] . That last report is similar to the findings presented here where CTX levels, at baseline and 12 months, did not differ between radiological progressors and non-progressors. Taken together, the reduction in CTX-1 is considered to reflect reduced systemic inflammation related to generalized bone resorption with no specific effects of prednisolone.
The present study has some limitations. First, not all patients in the original randomized study were included Data are presented as median (IQR). Data were analysed using a mixed linear model with the variables log-transformed. For P-values, see explanation in Table 4 .
a Variables that are included in the interaction calculations.
www.rheumatology.oxfordjournals.org in this mechanistic study as patients not having radiographs at both baseline and 2 years were excluded. However, the excluded patients did not differ in baseline characteristics from those included. Furthermore, the patients were not blinded to the prednisolone therapy, which could affect outcome as remission. This possibility seems though less possible as the objective variable ESR has the greatest effect of the four components on the total DAS28 score [44] . Another limitation is that we measured sRANKL, and got a large proportion of the samples outside the measuring range [45] .
Conclusion
Addition of low-dose prednisolone to DMARD treatment reduces inflammation and progression of radiological damage. One of the mechanisms by which low-dose prednisolone treatment protects inflamed joints from structural damage might be by down-regulating the synthesis of MMPs, here seen as a reduction of 1CTP. The more marked reduction of 1CTP in prednisolone-treated patients was still present when only patients in remission were studied. This implies the presence of a prednisolonespecific effect in addition to reduced inflammatory activity. Another mechanism might be decreased osteoclast activation, as shown by a stable ratio of OPG/RANKL in prednisolone-treated patients in contrast to a decreased ratio in patients not treated with prednisolone.
Rheumatology key messages
. Low-dose prednisolone in early RA has specific effects on 1CTP levels and OPG/RANKL ratio. . In RA, effect of prednisolone on bone markers is only partly dependent on reduced inflammation. . Reduction of 1CTP level by low-dose prednisolone in RA is associated with reduced radiological progression.
